Indirect comparison of nivolumab ± ipilimumab (CheckMate 032) versus other treatments for recurrent small-cell lung cancer
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Indirect comparison of nivolumab ± ipilimumab (CheckMate 032) versus other treatments for recurrent small-cell lung cancer
Authors
Keywords
-
Journal
Journal of Comparative Effectiveness Research
Volume -, Issue -, Pages -
Publisher
Future Medicine Ltd
Online
2019-06-25
DOI
10.2217/cer-2018-0130
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
- (2018) Matthew D. Hellmann et al. CANCER CELL
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- (2018) Leora Horn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor mutational burden (TMB) as a biomarker of response to immunotherapy in small cell lung cancer
- (2018) Yanis Boumber Journal of Thoracic Disease
- P1.15-003 Survival by Response to First-line Platinum-Based Therapy Among Patients With Extensive Disease Small Cell Lung Cancer
- (2017) M. Danese et al. Journal of Thoracic Oncology
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Treatment advances in small cell lung cancer (SCLC)
- (2017) Saiama N. Waqar et al. PHARMACOLOGY & THERAPEUTICS
- O1-21-6A PHASE III STUDY OF CDDP, ETOP AND IRINOTECAN VS. TOPOTECAN AS 2ND-LINE CHEMOTHERAPY FOR SENSITIVE RELAPSED SCLC: JCOG0605
- (2017) Takashi Seto et al. ANNALS OF ONCOLOGY
- Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial
- (2016) Koichi Goto et al. LANCET ONCOLOGY
- Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
- (2016) Scott J Antonia et al. LANCET ONCOLOGY
- A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer
- (2016) Alberto A. Chiappori et al. ONCOLOGIST
- Second-Line Oral Chemotherapy (Lomustine, Cyclophosphamide, Etoposide) Versus Intravenous Therapy (Cyclophosphamide, Doxorubicin, and Vincristine) in Patients With Relapsed Small Cell Lung Cancer: A Randomized Phase II Study of GFPC 0501
- (2015) Radj Gervais et al. Clinical Lung Cancer
- Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline
- (2015) Charles M. Rudin et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy
- (2015) Tracey L. Evans et al. Journal of Thoracic Oncology
- Randomized phase II trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer: North Japan Lung Cancer Study Group trial 0702
- (2015) Akira Inoue et al. LUNG CANCER
- Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032
- (2015) Matthew Taylor et al. Journal for ImmunoTherapy of Cancer
- Small cell lung cancer: Where do we go from here?
- (2014) Lauren Averett Byers et al. CANCER
- The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation
- (2014) E Loveman et al. HEALTH TECHNOLOGY ASSESSMENT
- Southwest Oncology Group S0802: A Randomized, Phase II Trial of Weekly Topotecan With and Without Ziv-Aflibercept in Patients With Platinum-Treated Small-Cell Lung Cancer
- (2014) Jeffrey W. Allen et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer
- (2014) Joachim von Pawel et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2013) M. Fruh et al. ANNALS OF ONCOLOGY
- Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers
- (2013) Jeroen P Jansen et al. BMC Medicine
- Evidence Synthesis for Decision Making 4
- (2013) Sofia Dias et al. MEDICAL DECISION MAKING
- Meta-regression models to address heterogeneity and inconsistency in network meta-analysis of survival outcomes
- (2012) Jeroen P Jansen et al. BMC Medical Research Methodology
- How to Use an Article Reporting a Multiple Treatment Comparison Meta-analysis
- (2012) Edward J. Mills et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Network meta-analysis of survival data with fractional polynomials
- (2011) Jeroen P Jansen BMC Medical Research Methodology
- Small-cell lung cancer
- (2011) Jan P van Meerbeeck et al. LANCET
- Network meta-analysis of parametric survival curves
- (2011) Mario J. N. M. Ouwens et al. Research Synthesis Methods
- Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: A tutorial
- (2010) Beth S Woods et al. BMC Medical Research Methodology
- Randomized Phase II Trial of Single-Agent Amrubicin or Topotecan as Second-Line Treatment in Patients With Small-Cell Lung Cancer Sensitive to First-Line Platinum-Based Chemotherapy
- (2010) Robert Jotte et al. JOURNAL OF CLINICAL ONCOLOGY
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- New Advances in the Second-Line Treatment of Small Cell Lung Cancer
- (2009) J. L. Hurwitz et al. ONCOLOGIST
- The BUGS project: Evolution, critique and future directions
- (2009) David Lunn et al. STATISTICS IN MEDICINE
- Randomized Phase II Trial Comparing Amrubicin With Topotecan in Patients With Previously Treated Small-Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 0402
- (2008) Akira Inoue et al. JOURNAL OF CLINICAL ONCOLOGY
- Symptom Assessment in Relapsed Small Cell Lung Cancer: Cross-Validation of the Patient Symptom Assessment in Lung Cancer Instrument
- (2008) Lei Chen et al. Journal of Thoracic Oncology
- A multicenter randomized phase II study of the irinotecan/gemcitabine doublet versus irinotecan monotherapy in previously treated patients with extensive stage small-cell lung cancer
- (2008) Athanasios G. Pallis et al. LUNG CANCER
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started